Media Pooling Strategy Added to SARS-CoV-2 RT-PCR Test
The ViroKey SARS-CoV-2 RT-PCR Test v2.0 has the additional capability to be used for pooling, using a three-in-one media pooling strategy.
The ViroKey SARS-CoV-2 RT-PCR Test v2.0 has the additional capability to be used for pooling, using a three-in-one media pooling strategy.
LumiraDx announced that the intended use for its FDA EUA-authorized SARS-CoV-2 Antigen Test has been expanded to include asymptomatic individuals.
ARCpoint Labs is utilizing its national network of diagnostic testing facilities to help travelers find convenient locations for COVID-19 testing.
LumiraDx has announced receiving FDA EUA for its SARS-CoV-2 Ab test, which is used to help identify an adaptive immune response to SARS-CoV-2.
Read MoreNanoDx, Inc., has entered into a licensing agreement with IBM Research for use of its nanoscale sensors for accurate, rapid testing.
Read MoreTechnology developed by UCL and AHRI researchers could transform the ability to accurately interpret HIV test results.
Read MoreRoche has announced that the U.S. FDA has granted EUA for the cobas SARS-CoV-2 Nucleic acid test for use on the cobas Liat System.
Read MorePandemic preparedness requires long-term investments in disease surveillance, diagnostics, therapeutics, and vaccine research.
Read MoreThe reporting app helps facilitate SARS-CoV-2 testing and result reporting from BD Veritor Plus System.
Read MoreMailing a package of SARS-CoV-2 tests to every household in America and asking people to use them once a week could greatly reduce total infections and mortality at a justifiable cost, according to a study led by the Yale School of Public Health.
Read MoreThe antigen test enables certain individuals to rapidly collect and test their samples at home without needing to send them to a laboratory for analysis.
Read MoreThese funds will enable the company to develop a point-of-care antigen test that delivers results in less than 6 minutes.
Read MoreA study from the CDC found that BinaxNOW catches most infectious cases but may miss nearly two-thirds of covid-19 infections in people without symptoms.
Read MoreQuantuMDx expects to achieve CE-IVD marking for its Q-POC system in early 2021, following a release for research use only.
Read MoreThe easy-to-use, visually read test could expand testing for covid-19 to diverse point-of-care locations.
Read MoreAbbott and eMed expect to deliver and administer 30 million BinaxNow tests in the first quarter of 2021, with an additional 90 million in the second quarter.
Read MoreThe Lucira Covid-19 All-In-One Test Kit is a molecular (real-time loop mediated amplification reaction) single-use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes covid-19.
Read MoreThis additional BARDA funding supports a test designed to read the immune system and rapidly diagnose acute infection at the point of care.
Read More